Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up

The tumor necrosis factor-α (TNF-α) antagonists infliximab, adalimumab, and etanercept have been approved for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Manifestations of demyelinating disease have been rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Signore, Sandra C., Brauns, Birka, Schütze, Gunther, Dohm, Christoph P., Bähr, Mathias, Mössner, Rotraut, Kermer, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836197/
https://www.ncbi.nlm.nih.gov/pubmed/29515419
http://dx.doi.org/10.1159/000485499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836197/
https://www.ncbi.nlm.nih.gov/pubmed/29515419
http://dx.doi.org/10.1159/000485499

Ejemplares similares